Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development
This article, published in Clinical Infectious Diseases, reports on the Shigella serotypes identified in the Global Enteric Multicenter Study conducted in Africa and Asia in order to guide vaccine development efforts. The authors found that Shigella dysenteriae and S. boydii accounted for 5.0% and 5.4%, respectively, of 1,130 Shigella case isolates; S. flexneri comprised 65.9% and S. sonnei 23.7%. Five serotypes/subserotypes comprised 89.4% of S. flexneri, including S. flexneri 2a, 6, 3a, 2b, and 1b. They conclude that a broad-spectrum Shigella vaccine must protect against S. sonnei and 15 S. flexneri serotypes/subserotypes.
Author: Livio S, Strockbine NA, Panchalingam S, et al.
» Visit web page (English)
(Located at cid.oxfordjournals.org)
Citation: Livio S, Strockbine NA, Panchalingam S, et al. Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development. Clinical Infectious Diseases. 2014;59(7):933-941.
Resource types: Peer-reviewed journal
Diseases/vaccines: Shigellosis and enterotoxigenic Escherichia coli (ETEC)